Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you've designed a clinical trial in cancer prevention or survivorship that can shift clinical practice, the NCI will fund it—but you must have IRB approval and rigor to match a full-scale Phase trial.
Report stale or inaccurate summary
What this is
This R01 grant program from the National Cancer Institute supports clinical trials investigating cancer prevention, screening, early detection, and survivorship improvements. The program explicitly excludes oncologic therapy and diagnostic trials, focusing instead on studies with potential to reduce cancer burden through better prevention, interception, healthcare delivery, quality of life, and survivorship. Eligible applicants are broad—nonprofits, small businesses, universities, state/local governments, and tribal organizations can apply. Applications require NIH-defined clinical trial methodology and must align with NCI Division of Cancer Prevention or Division of Cancer Control and Population Sciences priorities.
Who can apply
Nonprofits with or without 501(c)(3) status, small businesses, for-profit organizations (non-small-business), public/private universities, state and local governments, tribal organizations, and other institutional entities are eligible. No geographic restrictions stated. Solo founders or unfunded researchers would struggle without institutional affiliation.
Eligible applicant types
- County governments
- Public housing authorities/Indian housing authorities
- For profit organizations other than small businesses
- City or township governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal governments (Federally recognized)
- State governments
- Small businesses
- Special district governments
- Independent school districts
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Full description — from the agency
Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.
Topics: cancer prevention clinical trials · early detection screening · cancer survivorship · cancer interception · investigator-initiated research · NIH R01 grant
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.